# Lene Gerlach

> Lene Gerlach is a seed investor at Women in Life Science Denmark backing Health Care. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Women in Life Science Denmark](https://shizune.co/investors/profile/women-in-life-science-denmark)
- Location: Copenhagen, Denmark
- Total investments: 6
- Last investment: May 2024
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/lene-gerlach-87426442
- X (Twitter): https://twitter.com/LeneGerlach
- Website: https://x.com/LeneGerlach
- Facebook: https://www.facebook.com/lene.gerlach

Lene Gerlach is a seed investor at Women in Life Science Denmark in Copenhagen focused on Health Care and Biotechnology. Lene Gerlach currently works as a Board Member for ArgusEye. She previously worked at Bestyrelseskvinder as a Member. Lene Gerlach attended Probana Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 50% |
| Biotechnology | 3 | 50% |
| Sensor | 1 | 17% |
| Medical | 1 | 17% |
| Software | 1 | 17% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 50% |
| Series A | 1 | 17% |
| Venture - Series Unknown | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 3 | 50% |
| Sweden | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ArgusEye | ArgusEye is a biotechnology company that provides sensor solutions for real-time detection of biological systems and processes. ArgusEye's patented sensor technology is the result of extensive academic research and is based on nanoplasmonic sensing with fiber optics. By adding customized receptors, ArgusEye can offer flexible and sensitivesensing systems for a variety of targets. | $3M | Venture - Series Unknown | May 13, 2024 |  |
| Synklino | Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation. | $32M | Series A | Jun 08, 2022 |  |
| Octarine Bio | Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $1.2M | Seed | Mar 11, 2021 |  |
| Octarine Bio | Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $1.8M | Seed | Nov 12, 2020 |  |
| Synklino | Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation. |  | Seed | Sep 29, 2020 |  |
| Cerebriu | Cerebriu is a health tech company developing machine learning in medical imaging that improves workflow efficiency and quality in radiology.Its software solution Cerebriu Apollo achieves the company's aim by automating image acquisition protocols and triage during MRI brain acquisition providing decision support at key stages of thediagnostic process. The company covers findings of the brain, starting with brain MRI, including stroke, bleeds, and tumors, following MS, dementia, and TBI in brain CT. | $960K | Seed | May 08, 2020 |  |

6 of 6 investments shown.

## Co-investors
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden-43cc) — VC Fund, 5 deals together
- [EIR Ventures](https://shizune.co/investors/profile/eir-ventures) — VC Fund, 2 deals together
- [Oskare Capital](https://shizune.co/investors/profile/oskare-capital) — VC Fund, 2 deals together
- [Crista Galli Ventures](https://shizune.co/investors/profile/crista-galli-ventures) — VC Fund, 1 deal together
- [KMD Venture](https://shizune.co/investors/profile/kmd-venture) — VC Fund, 1 deal together
- [Maj Invest Equity](https://shizune.co/investors/profile/maj-invest-equity) — VC Fund, 1 deal together

## About Women in Life Science Denmark

VC Fund · Copenhagen, Denmark

WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science.

2 contacts available at Women in Life Science Denmark.

| Name | Title | Profile |
| --- | --- | --- |
| Lene Gerlach | Founder and Chairperson | https://shizune.co/investors/profile/lene-gerlach |
| Kirsten Drejer | CEO and Co-Founder | https://shizune.co/investors/profile/kirsten-drejer |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Lene Gerlach invest in?

Lene Gerlach invests primarily in Health Care, Biotechnology and Sensor startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Lene Gerlach last invest?

The most recent investment recorded for Lene Gerlach closed in May 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co